From the Right · Read · October 23, 2026
Oct 22 · Moderna and Merck's personalized mRNA melanoma vaccine cuts the risk of recurrence or death by 42%, and Moderna shares tumble after the data leaks early
Just the News: Moderna stock plummets after reported leak of disappointing cancer-vaccine data
Grade D (64/100). Moderna closes down nearly 18% after OncologyCentral posted the study early; the 42% and 38% figures, credited to the Wall Street Journal
Lehrer score 64/100 (−12 loaded wording: headline: 'disappointing cancer-vaccine data' (verdict in the outlet's own voice; the body calls the results 'apparently positive'); −24 factual error: ¶4: 'The company had claimed in August that its vaccine ... had prevented melanoma ... from returning or spreading'. The August announcement was a lower risk, not prevention: Forbes reports it 'significantly lowered the odds of cancer returning or spreading' and CNN a 42% lower risk). Fixed scale: 90+ A, 80s B, 70s C, 60s D, under 60 F → D.
headline: 'disappointing cancer-vaccine data' (verdict in the outlet's own voice; the body calls the results 'apparently positive'); ¶4: 'The company had claimed in August that its vaccine ... had prevented melanoma ... from returning or spreading'. The August announcement was a lower risk, not prevention: Forbes reports it 'significantly lowered the odds of cancer returning or spreading' and CNN a 42% lower risk
Splits: Moderna closes down nearly 18% after OncologyCentral posted the study early; the 42% and 38% figures, credited to the Wall Street Journal
- Broken. Rule: loaded wording (headline: 'disappointing cancer-vaccine data' (verdict in the outlet's own voice; the body calls the results 'apparently positive'))
- Broken. Rule: factual error (¶4: 'The company had claimed in August that its vaccine ... had prevented melanoma ... from returning or spreading'. The August announcement was a lower risk, not prevention: Forbes reports it 'significantly lowered the odds of cancer returning or spreading' and CNN a 42% lower risk)